| mRNA |
Erlotinib |
UHNBreast |
pan-cancer |
AAC |
0.55 |
0.04 |
| mRNA |
Doxorubicin |
GDSC1000 |
pan-cancer |
AAC |
-0.078 |
0.04 |
| mRNA |
BRD9647 |
CTRPv2 |
pan-cancer |
AAC |
0.076 |
0.04 |
| mRNA |
Bortezomib |
CTRPv2 |
pan-cancer |
AAC |
0.071 |
0.04 |
| mRNA |
BRD-K99006945 |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.04 |
| mRNA |
GDC-0941 |
gCSI |
pan-cancer |
AAC |
-0.13 |
0.05 |
| mRNA |
NVP-BEZ235 |
GDSC1000 |
pan-cancer |
AAC |
-0.073 |
0.05 |
| mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.071 |
0.05 |
| mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.072 |
0.05 |
| mRNA |
Crizotinib |
gCSI |
pan-cancer |
AAC |
-0.12 |
0.05 |